Rising Insulin Prices Impact Patients’ Diabetes Management, Holistic Wellness
Because several pharmaceutical companies pulled back from the federal 340B program last fall, many patients with diabetes are now seeing skyrocketing insulin prices.
Because several pharmaceutical companies pulled back from the federal 340B program last fall, many patients with diabetes are now seeing skyrocketing insulin prices, according to Anne Webster, NP, with UnityPoint Health.
Webster said she has been forced to prescribe less effective insulin options in recent months and has seen patients beginning to ration their medications. In addition to impacting their physical health, Webster said she has seen patients struggling with their mental and financial wellbeing over the last few months, and she sees no end in sight. The only solution, she said, is for Health and Human Services Director Xavier Becerra, JD, to enforce federal policies to ensure affordable medication access.
Treating Anxiety in Children and Teens Who Present Comorbidities
June 8th 2020Susan Van Cleve, Clinical Professor and Primary Care Pediatric Nurse Practitioner Program Director, University of Iowa College of Nursing, discusses how to identify and treat anxiety in children and teens who present comorbidities.
